Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 9

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 9
---
 1,156  
     (1,235)
  
    Net cash used in operating activities 
     (6,769,279) 
     (5,587,634)

    Cash flows from investing activities 

    Purchase of property and equipment 
     (60,567) 
     (79,082)
  
    Net cash used in investing activities 
     (60,567) 
     (79,082)

    Cash flows from financing activities 

    Proceeds from issuance of Common Stock from direct offering 
     9,271,534  
     2,950,000 
  
    Proceeds from exercise of options 
     —  
     74,899 
  
    Proceeds from exercise of warrants 
     4,813,742  
     1,343,377 
  
    Proceeds from issuance of Convertible Preferred Stock 
     990,000  
     — 
  
    Payment of offering costs for financing activities 
     (1,418,459) 
     (785,167)
  
    Payment on loans payable, net 
     (11,795) 
     — 
  
    Proceeds from loans payable 
     —  
     288,760 
  
    Principal repayments on finance leases 
     (251,272) 
     (270,143)
  
    Net cash provided by financing activities 
     13,393,750  
     3,601,726 

    Net increase (decrease) in cash and cash equivalents 
     6,563,904  
     (2,064,990)
  
    Cash and cash equivalents at beginning of period 
     1,105,291  
     2,821,570 
  
    Cash and cash equivalents at end of period 
    $7,669,195  
    $756,580 

    Supplemental disclosures of cash flow information: 

    Interest expense paid in cash 
    $3,655  
    $13,541 
  
    Income taxes paid in cash 
     40,861  
     11,650 

The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8

bioAffinity
Technologies, Inc.

Notes
to Condensed Consolidated Financial Statements

(unaudited)

Note
1. NATURE OF OPERATIONS